JP2023517275A - 脂質ナノ粒子 - Google Patents

脂質ナノ粒子 Download PDF

Info

Publication number
JP2023517275A
JP2023517275A JP2022544069A JP2022544069A JP2023517275A JP 2023517275 A JP2023517275 A JP 2023517275A JP 2022544069 A JP2022544069 A JP 2022544069A JP 2022544069 A JP2022544069 A JP 2022544069A JP 2023517275 A JP2023517275 A JP 2023517275A
Authority
JP
Japan
Prior art keywords
lipid
mol
peg
mrna
peg2000
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022544069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517275A5 (https=
Inventor
コケル，ステファン デ
ビーバース，サンネ
シッフフェラーズ，レイモンド，ミッシェル
コーユマンズ，サンダー，アレクサンダー，アントニウス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel VUB
Original Assignee
Vrije Universiteit Brussel VUB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Brussel VUB filed Critical Vrije Universiteit Brussel VUB
Publication of JP2023517275A publication Critical patent/JP2023517275A/ja
Publication of JP2023517275A5 publication Critical patent/JP2023517275A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022544069A 2020-01-21 2021-01-21 脂質ナノ粒子 Pending JP2023517275A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20152995.5 2020-01-21
EP20152995 2020-01-21
EP20152938 2020-01-21
EP20152938.5 2020-01-21
EP20179434.4 2020-06-11
EP20179434 2020-06-11
PCT/EP2021/051290 WO2021148511A1 (en) 2020-01-21 2021-01-21 Lipid nanoparticles

Publications (2)

Publication Number Publication Date
JP2023517275A true JP2023517275A (ja) 2023-04-25
JP2023517275A5 JP2023517275A5 (https=) 2024-02-13

Family

ID=74215945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022544069A Pending JP2023517275A (ja) 2020-01-21 2021-01-21 脂質ナノ粒子

Country Status (12)

Country Link
US (1) US20230067722A1 (https=)
EP (1) EP4093373A1 (https=)
JP (1) JP2023517275A (https=)
KR (1) KR20230002300A (https=)
CN (1) CN115697298A (https=)
AU (1) AU2021211894A1 (https=)
BR (1) BR112022013837A2 (https=)
CA (1) CA3168696A1 (https=)
IL (1) IL294624A (https=)
MX (1) MX2022009018A (https=)
TW (1) TW202139975A (https=)
WO (1) WO2021148511A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020182993A1 (en) * 2019-03-13 2020-09-17 Etherna Immunotherapies Nv Mrna vaccine
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
EP4346901A4 (en) * 2021-06-01 2025-04-23 The University of British Columbia MRNA DELIVERY USING LIPID NANOPARTICLES
CA3238764A1 (en) * 2021-11-23 2023-06-01 Siddharth Patel A bacteria-derived lipid composition and use thereof
CN114716355B (zh) * 2022-04-02 2023-09-05 华南理工大学 一种脂质化合物、包含其的组合物及应用
CN115887674B (zh) * 2022-04-29 2023-08-25 北京剂泰医药科技有限公司 脂质纳米颗粒
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
CN115414476B (zh) * 2022-08-15 2023-07-14 珠海暨创硒源纳米科技有限公司 一种改性氧化镁、含镁纳米颗粒水溶液及其制备方法与在制备佐剂中的应用
WO2024064206A1 (en) * 2022-09-20 2024-03-28 Emory University Lipid nanoparticles comprising nucleic acids encoding therapeutic genes and uses in medical methods
CN116763756A (zh) * 2022-10-11 2023-09-19 中国科学院化学研究所 一种脂质纳米颗粒及其制备方法和应用
JP7813825B2 (ja) * 2023-02-07 2026-02-13 株式会社微生物化学研究所 ワクチン
CN115998714B (zh) * 2023-03-20 2023-06-30 威瑞生物科技(昆明)有限责任公司 一种脂质纳米颗粒、递送系统及递送系统的制备方法
EP4442256A1 (en) 2023-04-04 2024-10-09 Københavns Universitet Lipid nanoparticle compositions
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117159492A (zh) * 2023-07-27 2023-12-05 广州制高点医药科技有限公司 一种含有唾液酸脂质衍生物的脂质纳米颗粒及其应用
CN120359024A (zh) 2023-10-12 2025-07-22 科百博生物股份有限公司 脂质纳米颗粒

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523870A (ja) * 2011-06-08 2014-09-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 切断可能な脂質
WO2016118725A1 (en) * 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2019131580A1 (ja) * 2017-12-27 2019-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 カチオン性脂質
WO2019141814A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles
JP2019525901A (ja) * 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305769A1 (en) * 2008-11-17 2011-12-15 Enzon Pharmaceuticals, Inc. Branched cationic lipids for nucleic acids delivery system
EP3243504A1 (en) * 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
KR101766408B1 (ko) * 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
AU2014340149B2 (en) * 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
HUE058792T2 (hu) 2013-11-12 2022-09-28 Univ Brussel Vrije RNS-transzkripciós vektor és felhasználása
PL3386484T3 (pl) * 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
US11458106B2 (en) * 2016-05-09 2022-10-04 Astrazeneca Ab Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
CN109563511A (zh) * 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法
WO2018175783A1 (en) * 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523870A (ja) * 2011-06-08 2014-09-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 切断可能な脂質
WO2016118725A1 (en) * 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
JP2019525901A (ja) * 2016-06-14 2019-09-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 脂質ナノ粒子の安定化製剤
WO2019131580A1 (ja) * 2017-12-27 2019-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 カチオン性脂質
WO2019141814A1 (en) * 2018-01-18 2019-07-25 Etherna Immunotherapies Nv Lipid nanoparticles

Also Published As

Publication number Publication date
EP4093373A1 (en) 2022-11-30
BR112022013837A2 (pt) 2022-09-13
MX2022009018A (es) 2022-08-11
AU2021211894A1 (en) 2022-09-01
US20230067722A1 (en) 2023-03-02
TW202139975A (zh) 2021-11-01
WO2021148511A1 (en) 2021-07-29
CA3168696A1 (en) 2021-07-29
KR20230002300A (ko) 2023-01-05
IL294624A (en) 2022-09-01
CN115697298A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
JP2023517275A (ja) 脂質ナノ粒子
US20240261381A1 (en) Lipid nanoparticles
JP7096282B2 (ja) 免疫療法のためのｒｎａ製剤
JP7333563B2 (ja) 脂質ナノ粒子
JP6716600B2 (ja) Ｒｎａ及び水溶性の治療有効化合物を標的細胞に送達するための脂質粒子製剤
TW202146031A (zh) 適用於治療之微脂體rna配製物的製備及儲存
US20230114808A1 (en) Therapeutic rna for prostate cancer
JP2022527830A (ja) 治療に適したリポソームｒｎａ製剤の調製および保存
JP2024535766A (ja) 治療に適した脂質ベースのｒｎａ製剤
RU2837542C1 (ru) Липидные наночастицы
RS58794B1 (sr) Formulacija rnk za imunoterapiju
TWI920113B (zh) 脂質奈米粒子
HK40087510A (zh) 脂质纳米颗粒
TW202304505A (zh) 脂質奈米粒子
HK40094060A (zh) 脂质纳米颗粒
JP2024514364A (ja) 緩衝物質を含むｒｎａ組成物ならびにその製造、保存および使用のための方法
WO2026047192A1 (en) Ionizable lipids
HK40113162A (zh) 多核苷酸组合物及其用途

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251009